These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
115 related articles for article (PubMed ID: 9536266)
1. Inhibition of HIV-1 replication by combined expression of gag dominant negative mutant and a human ribonuclease in a tightly controlled HIV-1 inducible vector. Cara A; Rybak SM; Newton DL; Crowley R; Rottschafer SE; Reitz MS; Gusella GL Gene Ther; 1998 Jan; 5(1):65-75. PubMed ID: 9536266 [TBL] [Abstract][Full Text] [Related]
2. Inhibition of HIV-1 replication by novel lentiviral vectors expressing transdominant Rev and HIV-1 env antisense. Mautino MR; Morgan RA Gene Ther; 2002 Apr; 9(7):421-31. PubMed ID: 11938457 [TBL] [Abstract][Full Text] [Related]
3. Generation of a packaging cell line for prolonged large-scale production of high-titer HIV-1-based lentiviral vector. Ni Y; Sun S; Oparaocha I; Humeau L; Davis B; Cohen R; Binder G; Chang YN; Slepushkin V; Dropulic B J Gene Med; 2005 Jun; 7(6):818-34. PubMed ID: 15693055 [TBL] [Abstract][Full Text] [Related]
4. High level inhibition of HIV replication with combination RNA decoys expressed from an HIV-Tat inducible vector. Fraisier C; Irvine A; Wrighton C; Craig R; Dzierzak E Gene Ther; 1998 Dec; 5(12):1665-76. PubMed ID: 10023446 [TBL] [Abstract][Full Text] [Related]
5. Inhibition of human immunodeficiency virus type 1 (HIV-1) replication by HIV-1-based lentivirus vectors expressing transdominant Rev. Mautino MR; Keiser N; Morgan RA J Virol; 2001 Apr; 75(8):3590-9. PubMed ID: 11264348 [TBL] [Abstract][Full Text] [Related]
6. Long-term protection against HIV-1 infection conferred by tat or rev antisense RNA was affected by the design of the retroviral vector. Peng H; Callison D; Li P; Burrell C Virology; 1996 Jun; 220(2):377-89. PubMed ID: 8661389 [TBL] [Abstract][Full Text] [Related]
7. Inhibition of simian/human immunodeficiency virus replication in CD4+ T cells derived from lentiviral-transduced CD34+ hematopoietic cells. Braun SE; Wong FE; Connole M; Qiu G; Lee L; Gillis J; Lu X; Humeau L; Slepushkin V; Binder GK; Dropulic B; Johnson RP Mol Ther; 2005 Dec; 12(6):1157-67. PubMed ID: 16168713 [TBL] [Abstract][Full Text] [Related]
8. Inhibition of HIV-1 replication and infectivity by expression of a fusion protein, VPR-anti-integrase single-chain variable fragment (SFv): intravirion molecular therapies. BouHamdan M; Kulkosky J; Duan LX; Pomerantz RJ J Hum Virol; 2000; 3(1):6-15. PubMed ID: 10774802 [TBL] [Abstract][Full Text] [Related]
9. Regulation of HIV-1 envelope protein synthesis by Tat and Rev in 293 cells. Natarajan V; Radjendirane V; Salzman NP Virology; 1993 Sep; 196(1):122-9. PubMed ID: 8356789 [TBL] [Abstract][Full Text] [Related]
10. High transdominant RevM10 protein levels are required to inhibit HIV-1 replication in cell lines and primary T cells: implication for gene therapy of AIDS. Plavec I; Agarwal M; Ho KE; Pineda M; Auten J; Baker J; Matsuzaki H; Escaich S; Bonyhadi M; Böhnlein E Gene Ther; 1997 Feb; 4(2):128-39. PubMed ID: 9081703 [TBL] [Abstract][Full Text] [Related]
11. Inhibition of HIV-1 replication in primary human T cells transduced with an intracellular anti-HIV-1 p17 antibody gene. Tewari D; Notkins AL; Zhou P J Gene Med; 2003 Mar; 5(3):182-9. PubMed ID: 12666184 [TBL] [Abstract][Full Text] [Related]
12. Studies on the effect of the combined expression of anti-tat and anti-rev genes on HIV-1 replication. Caputo A; Rossi C; Bozzini R; Betti M; Grossi MP; Barbanti-Brodano G; Balboni PG Gene Ther; 1997 Apr; 4(4):288-95. PubMed ID: 9176513 [TBL] [Abstract][Full Text] [Related]
14. Defective lentiviral vectors are efficiently trafficked by HIV-1 and inhibit its replication. Klimatcheva E; Planelles V; Day SL; Fulreader F; Renda MJ; Rosenblatt J Mol Ther; 2001 Jun; 3(6):928-39. PubMed ID: 11407907 [TBL] [Abstract][Full Text] [Related]
15. A combination anti-HIV-1 gene therapy approach using a single transcription unit that expresses antisense, decoy, and sense RNAs, and trans-dominant negative mutant Gag and Env proteins. Ding SF; Lombardi R; Nazari R; Joshi S Front Biosci; 2002 Feb; 7():a15-28. PubMed ID: 11815282 [TBL] [Abstract][Full Text] [Related]
16. Expression of mutant and wild-type gag proteins for gene therapy in HIV-1 infection. Miele G; Lever AM Gene Ther; 1996 Apr; 3(4):357-61. PubMed ID: 8732168 [TBL] [Abstract][Full Text] [Related]
17. Anti-HIV effects of HIV vectors. Corbeau P; Wong-Staal F Virology; 1998 Apr; 243(2):268-74. PubMed ID: 9568026 [TBL] [Abstract][Full Text] [Related]
18. Regulated expression of a dominant negative form of Rev improves resistance to HIV replication in T cells. Liu J; Woffendin C; Yang ZY; Nabel GJ Gene Ther; 1994 Jan; 1(1):32-7. PubMed ID: 7584057 [TBL] [Abstract][Full Text] [Related]
19. An inducible packaging cell system for safe, efficient lentiviral vector production in the absence of HIV-1 accessory proteins. Pacchia AL; Adelson ME; Kaul M; Ron Y; Dougherty JP Virology; 2001 Mar; 282(1):77-86. PubMed ID: 11259192 [TBL] [Abstract][Full Text] [Related]
20. Rapid protection against human immunodeficiency virus type 1 (HIV-1) replication mediated by high efficiency non-retroviral delivery of genes interfering with HIV-1 tat and gag. Lori F; Lisziewicz J; Smythe J; Cara A; Bunnag TA; Curiel D; Gallo RC Gene Ther; 1994 Jan; 1(1):27-31. PubMed ID: 7584056 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]